BTMDNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
biote Corp.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$1.08−0.00 (-0.46%)
Close on Oct 19, 2026
- Market cap
- $30.92M
- P/E (TTM)
- 10.8
- Dividend yield
- –
biote Corp. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product Revenue | $43.38M | $43.90M | $45.29M | $46.95M | $47.66M | $47.03M | $48.29M | $49.81M | $48.11M | $46.04M | $44.94M | $44.83M | 98.1% | -9.0% |
| Pellet Procedures Product Revenue | $30.31M | $31.29M | $31.83M | $33.97M | $35.21M | $36.04M | $36.60M | $37.93M | $38.42M | $37.39M | $34.87M | $35.42M | 68.5% | -13.9% |
| Dietary Supplements | $11.36M | $11.04M | $11.68M | $11.18M | $10.75M | $9.27M | $10.07M | $10.32M | $8.24M | $7.39M | $9.14M | $8.48M | 25.7% | +5.7% |
| Disposable Trocars Product Revenue | $1.21M | $1.13M | $1.21M | $1.24M | $1.23M | $1.18M | $1.12M | $1.08M | $1.11M | $1.03M | $881.00K | $893.00K | 2.7% | -1.5% |
| Service Revenue | $851.00K | $1.04M | $1.12M | $1.00M | $1.21M | $1.97M | $1.55M | $1.58M | $1.06M | $769.00K | $768.00K | $726.00K | 1.9% | -29.4% |
| Shipping Fees And Other Product Revenue | $505.00K | $434.00K | $572.00K | $566.00K | $474.00K | $538.00K | $501.00K | $479.00K | $338.00K | $230.00K | $51.00K | $47.00K | 1.1% | +6.5% |
| Other Service Revenue | $406.00K | $578.00K | $583.00K | $433.00K | $535.00K | $1.31M | $876.00K | $702.00K | $470.00K | $221.00K | $206.00K | $171.00K | 0.9% | -24.1% |
| Contract-Term Services Revenue | $311.00K | $332.00K | $346.00K | $343.00K | $338.00K | $335.00K | $359.00K | $303.00K | $290.00K | $274.00K | $251.00K | $234.00K | 0.7% | -8.0% |
| Training Service Revenue | $134.00K | $130.00K | $190.00K | $227.00K | $333.00K | $326.00K | $311.00K | $573.00K | $298.00K | $274.00K | $311.00K | $321.00K | 0.3% | -59.8% |
| Shipping Fees Product Revenue | – | – | – | – | – | – | – | – | – | $59.00K | $51.00K | $47.00K | – | – |
| Compounding Pharmacy Product Revenue | – | – | – | – | – | – | – | – | – | $171.00K | – | – | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $44.00M | $44.70M | $46.10M | $47.70M | $48.60M | $48.70M | $49.60M | $51.60M | $48.60M | $46.40M | $182.58M | $726.00K | 99.5% | -9.5% |
| All Other | – | – | – | – | – | – | – | $0 | $0 | – | – | $0 | – | – |
From the segment and revenue-disaggregation notes of biote's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.